Table 3. Duration of survival and laboratory test(s) positive at initial diagnosis (n = 39).
| Duration of survival | No of patients (%) | Positive by PCR alone | Positive by RFFIT (CSF/serum) alone | Positive both by RFFIT (CSF/serum) and PCR |
|---|---|---|---|---|
| < 7 days | 4 (10.2%) | 4 (100%) | - | - |
| 7–15 days | 4(10.2%) | - | 2 (50%) | 2 (50%) |
| >15 days- 1 month | 8(20.5%) | - | 8 (100%) | - |
| >1 month-3 months | 7*(17.9%) | - | 5 (71.42%) | 2 (28.57) |
| >3 month-6 months | 6#(15.3%) | - | 6 (100%) | - |
| >6 months | 10^ (25.6%) | - | 9 (90%) | 1 (10%) |
*1 patient lost to follow-up after 2 months.
# 3 patients lost to follow-up after 6 months.
^2 patients died after 6 and 8 months of survival, respectively. 2 cases were lost to follow-up after 7 and 9 months of survival, respectively. 6 patients are still surviving as of June 30th 2018. All survivors (except 2 cases) had/continue to have poor functional outcomes.
5 patients who survived received no intensive care; 3 cases had atypical presentation and 2 had paralytic rabies. 2 patients each survived for 1–3 months and 3–6 months respectively; One survived for >6 months, and has recovered with good functional outcome.